In the United States, the rate of prostate cancer screening is down, and the number of men diagnosed with the disease has also dropped.
Men should regularly be screened for prostate cancer, the leading cause of cancer death for men in the United States.
Higher doses of radiation does not increase survival rates in low-risk prostate cancer.
Combination radiation and hormone therapy is more effective than hormone therapy alone for the treatment of prostate cancer.
PCPs should encourage physical activity, smoking cessation, and a healthy diet for PCa survivors.
Multiparametric magnetic resonance imaging reported high accuracy in diagnosing low-risk prostate cancers.
Low adherence rates for prostate cancer care may be target for future quality improvements.
Risk of long-term mortality is lower compared with watchful waiting.
Risk for advanced prostate cancer was 75% lower in men with high levels of 6-sulfatoxymelatonin -- a measure of melatonin breakdown in urine.
Even after adjustment, acute, chronic inflammation linked to lower PCa risk at two-year repeat biopsy.
Potential psychological harm associated with biopsy even in absence of cancer diagnosis
Drinking coffee may lower the risk for prostate cancer recurrence and disease progression.
Aids help men make more informed choices regarding PSA screening, but did not affect actual screening rates.
Men consuming a soy supplement on a daily basis saw no reduction in their chances of prostate cancer recurrence.
Replacing carbohydrates and animal fat with vegetable fat may reduce prostate cancer mortality.
Xofigo has been approved three months ahead of schedule to treat men with metastatic castration-resistant prostate cancer.
Regular, moderate exercise was associated with decreased prostate cancer risk in white, but not black, men.
The FDA has expanded the indication for abiraterone acetate to include treating late-stage castration-resistant prostate cancer before the administration of chemotherapy.
Choline C 11 Injection, a PET scan imaging agent, is now available for men with elevated PSA levels after earlier treatment for prostate cancer.
Lack of cancer expertise, continuity of care cited as barriers to receiving follow-up cancer care from primary care providers.
The Prostate Health Index is a non-invasive blood test that is 2.5-times more specific in detecting prostate cancer than prostate-specific antigen in patients with PSA values in the 4-10 ng/mL range.
Based on the evidence, the U.S. Preventive Services Task Force gave a grade D recommendation against PSA-based screening for men in the general U.S. population, regardless of age.
Many clinicians find it difficult to determine when it's appropriate to stop screening patients for prostate cancer.
Extended follow-up data from the European Randomized Study of Screening for Prostate Cancer shows screening reduced risk of death from prostate cancer, but not all-cause mortality.
Two studies offer data about the effects if vitamin E and saw palmetto on the prostate.
Drinking one to three cups of coffee a day was associated with a 30% lower risk of lethal prostate cancer.
A 20-year study has revealed that the rate of death from prostate cancer did not differ significantly between men who had been screened for the disease and men who had not.
U.S. primary care providers ordered twice as many office-based prostate-specific antigen tests in 2008 as they did in 1997.
A new study shows that a family history of other cancers in first-degree relatives may increase a patient's risk for prostate cancer, according to findings presented at the American Urological Association 2011 Annual Meeting.
The American Urological Association and the American Cancer Society disagree over when baseline screening should begin.